Anti–Heat Shock Protein 27 Antibody Levels and Diabetes Complications in the EURODIAB Study by Burt, Davina et al.
Anti–Heat Shock Protein 27 Antibody
Levels and Diabetes Complications in the
EURODIAB Study
DAVINA BURT, PHD
1
GRAZIELLA BRUNO, MD
1
NISH CHATURVEDI, MRCP
2
CASPER SCHALKWIJK, PHD
3
COEN D. STEHOUWER, PHD
3
DANIEL R. WITTE, PHD
4
JOHN H. FULLER, FRCP
5
SILVIA PINACH, MSC
1
PAOLO CAVALLO PERIN, MD
1
GABRIELLA GRUDEN, PHD
1
OBJECTIVE — Toassesswhetherserumanti–heatshockprotein27(HSP27)antibodylevels
are associated with micro- and macrovascular complications of type 1 diabetes.
RESEARCH DESIGN AND METHODS — Anti-HSP27 IgG antibody levels were mea-
sured in 531 type 1 diabetic subjects recruited as part of the cross-sectional analysis of the
EURODIAB Prospective Complications Study. Case subjects (n  363) were deﬁned as individ-
uals with one or more diabetes complications and control subjects (n  168) as individuals with
no evidence of any diabetes complication.
RESULTS — Anti-HSP27 levels were comparable in case and control subjects (19.6 arbitrary
units/ml [11.3–32.7] vs. 20.4 arbitrary units/ml [11.7–35.3], geometric mean [interquartile
range]), and there was no correlation between HSP27 and anti-HSP27 levels (r  0.01, P 
0.81). In logistic regression analysis, anti-HSP27 was not associated with the presence of com-
plications, even after adjustment for main risk factors.
CONCLUSIONS — Anti-HSP27 antibody levels are not a marker of vascular complications
in type 1 diabetes.
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H
eat shock protein (HSP27) is a
member of a family of proteins
whose intracellular expression is
increased to offset the deleterious effects
of cellular stresses (1). HSP27 is also re-
leased into the circulation and can induce
an autoimmune response with produc-
tion of anti-HSP27 antibodies (2).
The immune response against HSPs
has been implicated in the pathogenesis
of atherosclerosis in the general popula-
tion (3). In clinic-based cohorts, anti-
HSP27 antibody levels were found to be
associated with age and hypertension (4),
although not consistently (5), and in-
creased in patients with acute coronary
syndromes (4,6). However, no large epi-
demiological study has assessed anti-
HSP27 levels in stable patients with
established cardiovascular disease.
Type 1 diabetes is associated with a
greatly increased risk of vascular compli-
cations, and we have recently reported
that,intype1diabeticindividuals,higher
serum levels of HSP27 are independently
associated with a threefold-increased risk
of distal symmetrical polyneuropathy
(DSP) (7). In the same study base, we
have now assessed potential associations
between anti-HSP27 antibodies and both
micro- and macrovascular complications
of type 1 diabetes.
RESEARCH DESIGN AND
METHODS— The EURODIAB Pro-
spectiveComplicationsStudyisafollow-up
of the EURODIAB IDDM Complications
Study, designed to explore risk factors for
diabetes complications in 3,250 randomly
selectedpeoplewithtype1diabetes(8,9).
A cross-sectional, nested case-control
study was designed on the cohort re-
cruited at follow-up (10). Case subjects
were deﬁned as individuals with cardio-
vascular disease, proliferative retinopa-
thy, micro-/macroalbuminuria, or
neuropathy. Control subjects were se-
lected based on being completely free of
complications. Only subjects with serum
samples stored at 80°C within 2 h from
collection were included to reduce vari-
abilityduetoproteindegradation.Apply-
ing these criteria, this yielded 363 case
and 168 control subjects with full data on
complications and samples available for
analysis (7). The sample size provides a
power of 95% (0.05) to detect a dif-
ference in log anti-HSP27 of at least one-
third of an SD between case and control
subjects.
Anti-human HSP27 antibodies were
measured using an in-house enzyme-
linked immunosorbent assay. Microtiter
plates were coated with 1 g rh-HSP27
(Stressgen, Milan, Italy). After blocking
with 3% BSA, both standards and serum
samples (diluted 1:500) were added in
duplicateandincubatedovernightat4°C.
After 2-h incubation with peroxidase-
conjugated goat anti-human IgG (Sigma-
Aldrich, Milan, Italy), the substrate
3,3,5,5-tetramethylbenzidine dihydro-
chloride was added and the absorbance
readat450nmol/l.Sixserialdilutionsofa
control serum, highly positive for anti-
HSP27 IgG antibodies, were assayed in
every plate and used to generate a stan-
dard curve. The undiluted serum sample
was assigned 125 arbitrary units per mil-
liliter (AU/ml). The inter- and intra-assay
coefﬁcients of variation were 7.5 and 5.3%,
respectively. Serum IgG levels were deter-
mined by immunoturbidometry (Dade Be-
hring BN 100 Analyzer) with anti-IgG
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The coefﬁcients of variation for both intra-
and inter-assay were 4%.
Logistic regression analyses were
used to estimate the odds ratios of anti-
HSP27foranycomplication(albuminex-
cretion rate 20 g/min, retinopathy,
neuropathy, and cardiovascular disease),
independently of confounders and
known risk factors. The likelihood ratio
test was used to compare nested models
examining the role of age, sex, diabetes
duration, BMI, waist-to-hip ratio, A1C,
blood pressure, lipids, albumin excretion
rate,C-reactiveprotein,interleukin-6,tu-
mor necrosis factor-, homocysteine,
Amadori albumin, soluble E-selectin, sol-
uble vascular cell adhesion molecule, and
smokingstatus.Variableswereretainedin
theﬁnalmodeliftheyaddedsigniﬁcantlyto
thelikelihoodofmodelsortotheestimated
coefﬁcients of predictors. In light of the hy-
pothesis of a different role of anti-HSP27
antibodies in the pathogenesis of different
complications, logistic regression models
were also ﬁtted separately for each com-
plication. To assess the pattern of odds
ratios across increasing levels of serum
anti-HSP27 antibodies, levels were cat-
egorized into quartiles in control sub-
jects. Both linear and U-shaped trends
across quartiles were tested by entering
a single ordinal term and a quadratic
term into the models.
RESULTS— Anti-HSP27 levels were
measurable in all 531 samples and
showed a right skewed distribution. Val-
ues were similar in case and control sub-
jects (19.6 AU/ml [11.3–32.7] vs. 20.4
AU/ml [11.7–35.3], geometric mean [in-
terquartile range]), P  0.57), even after
adjustment for age and diabetes duration
(20.0vs.20.5AU/ml,P0.80).Further-
more, no relation was found between
HSP27 and anti-HSP27 serum levels (r 
0.01, P  0.81). In the logistic regression
analysis (Table 1), there was no signiﬁ-
cant association of anti-HSP27 antibodies
with either the “any complication” cate-
gory or with each complication sepa-
rately, apart from cardiovascular disease
(model 1 and 2). After adjustment for
main risk factors, however, this associa-
tion was no longer signiﬁcant (model 3).
No signiﬁcant trend, either linear or U-
shaped, across quartiles was present. Re-
sults were unmodiﬁed after adjustment
for IgG levels.
CONCLUSIONS — We have recently
reported that in type 1 diabetic patients,
serum levels of HSP27 are an indepen-
dentmarkerofDSP(7).Incontrast,inthe
present study, performed on the same
studybase,wefoundthatanti-HSP27lev-
elsweresimilarintype1diabeticpatients
with or without micro- and macrovascu-
lar complications, including DSP.
Although serum HSP27 levels are en-
hanced in type 1 diabetic patients with
DSP (7) and anti-HSP27 antibodies in-
duce neuronal apoptosis in vitro (11),
both the absence of relation between
HSP27 and anti-HSP27 levels and the
similarity in anti-HSP27 antibody values
among patients with or without DSP do
not support the hypothesis of a role of
anti-HSP27 antibodies in the pathogene-
sis of the neuronal damage in type 1
diabetes.
An immune response against HSPs
has been implicated in the pathogenesis
ofatherosclerosis(3).Thisistheﬁrstlarge
epidemiological study assessing circulat-
ing anti-HSP27 levels in type 1 diabetic
Table 1—Odds ratios for diabetes complications by anti-HSP27 values in the nested case-
control study within the EURODIAB study
Odds ratio
(95% CI)*
Odds ratio
(95% CI)†
Odds ratio
(95% CI)‡
All complications
Log anti-HSP27 1.07 (0.84–1.36) 1.00 (0.76–1.30) 1.12 (0.80–1.58)
Anti-HSP27 (AU/ml)
11.33 1.00 1.00 1.00
11.33–21.27 1.20 (0.72–2.02) 1.05 (0.59–1.89) 1.56 (0.75–3.28)
21.28–32.68 0.87 (0.51–1.48) 0.57 (0.31–1.05) 0.59 (0.28–1.28)
32.68 1.25 (0.75–2.09) 1.24 (0.69–2.23) 1.65 (0.80–3.43)
P for linear trend 0.65 0.87 0.56
DSP
Log anti-HSP27 1.10 (0.84–1.43) 0.97 (0.71–1.33) 0.94 (0.62–1.41)
Anti-HSP27 (AU/ml)
11.33 1.00 1.00 1.00
11.33–21.27 1.26 (0.71–2.24) 0.98 (0.49–1.94) 1.76 (0.70–4.40)
21.28–32.68 0.93 (0.51–1.70) 0.56 (0.27–1.15) 0.45 (0.18–1.21)
32.68 1.26 (0.71–2.24) 1.16 (0.59–2.30) 1.17 (0.48–2.87)
P for linear trend 0.66 0.98 0.63
Micro-/macroalbuminuria
Log anti-HSP27 1.02 (0.78–1.34) 0.98 (0.71–1.35) 0.96 (0.60–1.54)
Anti-HSP27 (AU/ml)
11.33 1.00 1.00 1.00
11.33–21.27 1.16 (0.66–2.05) 1.13 (0.58–2.23) 2.25 (0.80–6.34)
21.28–32.68 0.90 (0.50–1.63) 0.66 (0.33–1.34) 0.59 (0.20–1.66)
32.68 1.08 (0.61–1.92) 1.30 (0.65–2.59) 1.30 (0.47–3.62)
P for linear trend 0.99 0.82 0.79
Retinopathy
Log anti-HSP27 1.08 (0.83–1.38) 1.03 (0.76–1.39) 1.11 (0.74–1.67)
Anti-HSP27 (AU/ml)
11.33 1.00 1.00 1.00
11.33–21.27 1.28 (0.75–2.18) 1.37 (0.71–2.63) 2.28 (0.93–5.60)
21.28–32.68 0.97 (0.56–1.68) 0.66 (0.33–1.30) 0.69 (0.28–1.70)
32.68 1.25 (0.73–2.13) 1.50 (0.78–2.90) 2.09 (0.84–5.19)
P for linear trend 0.66 0.60 0.49
Cardiovascular disease
Log anti-HSP27 1.47 (1.09–1.99) 1.33 (0.93–1.90) 1.33 (0.85–2.07)
Anti-HSP27 (AU/ml)
11.33 1.00 1.00 1.00
11.33–21.27 1.72 (0.88–3.40) 1.56 (0.70–3.43) 1.72 (0.64–4.62)
21.28–32.68 1.50 (0.75–2.99) 0.76 (0.33–1.77) 0.69 (0.24–1.90)
32.68 2.41 (1.25–4.64) 2.43 (1.11–5.43) 2.35 (0.90–6.10)
P for linear trend 0.02 0.09 0.21
*Unadjusted. †Adjusted for age and diabetes duration. ‡Adjusted for age, diabetes duration, hypertension,
A1C, smoking, and log tumor necrosis factor-.
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tions.Strengthsofourstudyaretheuseof
a large representative sample of people
with type 1 diabetes and the ability to ac-
count for confounding by other risk fac-
tors and complications. There are
limitations, such as the cross-sectional
study design and the reduced power of
the analyses due to lower number of con-
trolsubjectscomparedwithcasesubjects.
However,altogether,ourdatadonotsup-
port the hypothesis that anti-HSP27 anti-
body levels are a suitable marker for
micro-/macrovascular complications in
type 1 diabetes.
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